Ultimately money can overcome almost any obstacle, but Hepalink's position, and to a certain extent that of Eastern (they're around 20% I believe)...I think it complicates issues, plus you have Royalty Preferred Shares held by Zenith. I believe it would make Resverlogix and/or just Apabetalone a very convoluted acquisition.
It should be noted, in case you're not aware...Eastern Capital, that's actually Kenneth Dart of the Dart Container fortune, he has a net worth estimated at over $6 billion. Eastern is simply his investment company.
I've long considered the most likely deal to be one where Shenzhen Hepalink takes Resverlogix over and maybe even uses an acquisition as an entry to the North American capital markets. Still, even while I think its 'most likely' I also see the share structure and ownership situation to be more than a little problematic, but just a bit less so if Hepa was doing the acquiring.
If you want to taste the fruit, you have to go out on a limb. But if you wait for the herd to move out on the limb....the branch tends to snap.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM